Clinical implications of assessment of apixaban levels in elderly atrial fibrillation patients: J-ELD AF registry sub-cohort analysis.
Shinya SuzukiTakeshi YamashitaMasaharu AkaoKen Okumuranull nullPublished in: European journal of clinical pharmacology (2020)
A high trough apixaban level in patients indicated for standard dose was not associated with adverse events, while a high apixaban level in patients indicated for a reduced dose was associated with bleeding requiring hospitalization.